on the afternoon of September 12, yirui technology (688301)2023 semi-annual performance presentation meeting was held at Shanghai roadshow center.

Yarui Technology is mainly engaged in the research and development, production, sales and service of new core components such as digital X-ray detectors, high-voltage generators, combined X-ray sources, and spherical tubes. In the first half of this year, Yirui Technology achieved operating income of 0.957 billion yuan, an increase of 32.83 percent over the same period last year; net profit attributable to shareholders of listed companies was 0.325 billion yuan, an increase of 17.43 percent over the same period last year; non-net profit attributable to shareholders of listed companies was 0.346 billion yuan, an increase of 25.86 percent over the same period last year; half-year gross profit margin was 58.25 percent; the company's performance growth was mainly due to the steady growth in flat panel detector sales in the first half, the rapid growth in sales of high-voltage generators and other core components.

At the performance meeting, some investors were curious about whether the company's high gross profit margin in recent years was sustainable.

In response, Zhao Kai, chief financial officer of Yirui Technology, said in an exchange that the company's gross profit margin was 58.25 in the first half of this year. Overall, the company's gross profit margin remained at a relatively stable level, mainly due to the mass production effect brought about by the further expansion of sales, the independent control of core components and core materials, the continuous implementation of measures to improve efficiency and reduce costs in the supply chain, and the optimization of product structure. In the long run, gross profit margin is affected by upstream raw material costs, manufacturing costs, product structure, capacity climbing and other factors. The company will continue to increase market expansion, continue to implement measures to increase efficiency and reduce costs, and adopt product upgrades, process improvements, and strengthen cost control. Measures to further enhance sales scale and market position to ensure long-term relative stability of gross profit margin.

in the financial indicators, some investors are also concerned about the accounts receivable at the end of the first half of this year, which increased by more than 70% compared with the amount at the end of last year. Zhao Kai explained to investors that in the first half of 2023, the company's overall sales continued to grow. At the same time, the company carried out the maintenance of strategic customers and major customers, and the account period was adjusted to a certain extent. At present, the account structure has not changed much. The specific detailed semi-annual report has also been disclosed. The accounts 0.593 billion within half a year and 0.61 billion within one year are within the controllable range as a whole, which is not expected to have much impact.

In recent years, digital X-ray detectors and other businesses have ushered in rapid development. CT business has always been the focus of Yirui Technology's layout. Some investors want to further understand the competitiveness, progress and performance of CT business.

According to Fang Zhiqiang, deputy general manager of Yirui Technology, the company has been increasing the research and development of CT detectors and their upstream core materials and components, striving to realize independent control of technology and production of core raw materials and components. In the first half of 2023, the company's two-dimensional collimators for medical CT and security CT entered the mass production stage one after another. At the same time, the research and development of new medical CT and the next generation of two-dimensional collimators are still continuing. The GOS scintillator suitable for medical CT detectors has made a breakthrough in research and development. The key indicators have reached the international leading level and are in the sample delivery evaluation and pilot stage.

In addition, in the recent investment direction, Fang Zhiqiang pointed out that while further strengthening the organic growth of digital X-ray detector-related businesses, the company will actively lay out new core components and raw materials for digital X-ray imaging, such as ceramic scintillator, high-voltage generator, ray source, ball tube, collimator, etc., which are strategically integrated with the company's future development, it enables the company to cover more product categories, penetrate more market segments, and strengthen its market position and competitive advantage.

It is worth noting that at this performance meeting, investors are also concerned about the impact of medical anti-corruption on the company. In this regard, Fang Zhiqiang explained that the company adopts a direct sales-based sales model, downstream customers are mainly medical, industrial X-ray imaging equipment manufacturers, X-ray imaging equipment manufacturers will be digital X-ray detectors and other parts assembled into a complete machine, and then sold to the terminal market. Medical institutions are not direct customers of the company, and pharmaceutical anti-corruption has no direct impact on the company's business. However, in the short term, the company's share price will inevitably be affected by market sentiment and other factors, there is some volatility.

He said that from the perspective of the long-term development of the industry, medical anti-corruption is conducive to creating a fairer competitive environment, helping the entire industry to develop in the direction of innovation, health, long-term, and high quality, and is more conducive to strong innovation capabilities and business compliance. The healthy development of compliant companies. The company has been continuously increasing the research and development of innovative technologies and products. In the first half of 2023, the company's R & D investment reached 0.12 billion billion yuan, an increase of 13.39 over the same period of last year. At the same time, the company has increased the layout of new core components of digital X-ray and made certain progress. While stabilizing its core competitiveness, the company will always adhere to law-abiding and compliance operation, strictly abide by the compliance bottom line, and maintain high quality and sustainable development.